The Technology Strategy Board has made some revisions to the criteria a project has to meet in order to receive a Knowledge Transfer Partnership (KTP) grant. This has caused some confusion. In order to obtain clarification, Neil Grice, the local Adviser visited the University last week for a meeting with School representatives.
Listed below are the current key award criteria:
- Project is for the development of a company capability, not a product.
- On completion, the company is left with a legacy, e.g. a new capability or process.
- Innovative – leading edge knowledge is transferred to the company. Can’t be done by employing consultants, needs research.
- Impact – the project makes a significant difference to the company which would not have happened without the KTP. University also receives significant results.
- Challenge – Stretching for University and company.
- Fits in with company strategy.
- Company is financially sound.
- Science and technology focussed. Difficult to obtain awards for social care, marketing and business development projects.
- Awards are most likely to be granted for projects with small/medium sized organisations.
If you require any further information on KTPs in general please contact Peter Delgado, Commercialisation and KTP Officer, e-mail – pdelgado@bournemouth.ac.uk
A Guide to Knowledge Transfer Partnerships










BU contributions to successful Global Health conference
New paramedic science paper by BU’s Dr. Ursula Rolfe
Congratulation on newly published systematic review
Equitable Partnerships in Global Health Research
Horizon Europe Cluster 3 (Civil Security for Society) 2026 Calls Now Open
MSCA Doctoral Networks 2026 Call Information Webinar
ESRC Festival of Social Science 2026: Application Deadline Extended to Thursday 25 June 2026
Reminder: Register for the ESRC Festival of Social Science 2026 Information Session
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease